Abstract
Objective To investigate the prognostic values of isocitrate dehydrogenase (IDH) and telomerase reverse transcriptase (TERT) promoter mutations in patients with lower-grade gliomas. Methods 260 patients with pathological diagnosis of lower-grade gliomas (WHO Ⅱ and WHOⅢ) were enrolled in the study, and their data were collected. Kaplan-Meier method was used to calculate the survival rates. Cox regression model was used to conduct multivariate analysis. Results The median survival time for IDH mut and IDH wt subgroups were 42.00 and 27.55 months with statistical significane (P=0.001). The median survival time for TERT mut and TERT wt subgroups were 42.00 and 33.50 months, respectively (P=0.660). The survival analysis for IDH/TERT combination demonstrated that the suvival of IDH wt/TERT mut subgroup was the worst (P=0.001), the survival of IDH mut subgroups were favourable (P=0.001). Conclusion IDH mutation has strong prognostic values for the survival of lower-grade gliomas. And TERT promoter mutation could contribute to IDH mutation in predicting the survival of lower-grade gliomas. IDH/TERT mutations could be significant prognostic factors influencing the survival of lower-grade gliomas. Key words: Isocitrate dehydrogenase; Telomerase reverse transcriptase; Lower-grade gliomas; Prognosis
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
